Insulin icodec is a novel, long-acting insulin analog designed for once-weekly administration that is in development for the treatment of diabetes. It is thought that a reduction in the frequency of basal insulin injections might facilitate treatment acceptance and adherence among patients with type 2 diabetes. In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) discusses how reduced frequency of dosing will improve adherence among patients. Prof. Chantal Mathieu also gives an update in the clinical development of insulin icodec the impact it will have on patient quality-of-life and clinical practice.
The abstract entitled: ‘Once Weekly Insulins: The Clinical Evidence to date’ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.
- What previous clinical evidence supports the use of once weekly insulin? (0:20)
- How will reduced frequency of dosing improve adherence and in turn glycaemic control? (1:27)
- Please could you give us an update on the clinical development of insulin icodec and basal insulin Fc (BIF)? (2:44)
- If approved, what will be the impact of once weekly insulin on patient quality-of-life and clinical practice? (5:37)
Disclosures: Chantal Mathieu discloses grant/research support from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of EASD 2022
Share this Video
Related Videos In Diabetes
John Doupis: ADA 83rd Scientific Sessions, 2023: Type 2 diabetes highlights
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant fees from Elli Lilly, Novo Nordisk, Abbott, Astra Zeneca and Boehringer Ingelheim. He […]
Chantal Mathieu: ADA 83rd Scientific Sessions, 2023: Research highlights
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and was FDA approved in November 2022; Orforglipron, an oral, non-peptide glucagon-like […]
Steven Nissen, ADA 2023: Bempedoic acid for cardiovascular disease risk: The CLEAR Outcomes trial
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven Nissen (Heart, Vascular and Thoracic Institute, Cleveland Clinic Center for Clinical Research, Cleveland, OH, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!